Have a personal or library account? Click to login
Paraneoplastic pemphigus associated with squamous cell carcinoma of the cervix Cover

Paraneoplastic pemphigus associated with squamous cell carcinoma of the cervix

Forum of Clinical Oncology
Volume 13 (2022): Issue 1 (December 2022)
By:
Open Access
|Sep 2022

References

  1. Paolino G, Didona D, Magliulo G, Iannella G, Didona B, Mercuri SR, et al. Paraneoplastic emphigus: insight into the autoimmune pathogenesis, clinical features and therapy. Int J Mol Sci. 2017; 18(12): 2532. DOI: <a href="https://doi.org/10.3390/ijms18122532" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3390/ijms18122532</a>
    Open DOISearch in Google ScholarBack to article
  2. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc. 2004; 9(1): 29–33. DOI: <a href="https://doi.org/10.1111/j.1087-0024.2004.00832.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/j.1087-0024.2004.00832.x</a>
    Open DOISearch in Google ScholarBack to article
  3. Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010; 8(8): 598–606. DOI: <a href="https://doi.org/10.1111/j.1610-0387.2010.07380.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/j.1610-0387.2010.07380.x</a>
    Open DOISearch in Google ScholarBack to article
  4. Miyashiro D, Sanches JA. Paraneoplastic skin disorders: a review. G Ital Dermatol Venereol. 2016; 151(1): 55–76.
    Search in Google ScholarBack to article
  5. Anhalt GJ, Kim SC, Stanley JR, Korman NJ, Jabs DA, Kory M, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med. 1990; 323(25): 1729–35. DOI: <a href="https://doi.org/10.1056/NEJM199012203232503" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1056/NEJM199012203232503</a>
    Open DOISearch in Google ScholarBack to article
  6. Joly P, Richard C, Gilbert D, Courville P, Chosidow O, Roujeau JC, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000; 43(4): 619–26. DOI: <a href="https://doi.org/10.1067/mjd.2000.107488" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1067/mjd.2000.107488</a>
    Open DOISearch in Google ScholarBack to article
  7. Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin. 2011; 29(3): 419–25, viii. DOI: <a href="https://doi.org/10.1016/j.det.2011.03.018" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.det.2011.03.018</a>
    Open DOISearch in Google ScholarBack to article
  8. Kim JH, Kim SC. Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa. Front Immunol. 2019; 10: 1259. DOI: <a href="https://doi.org/10.3389/fimmu.2019.01259" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.3389/fimmu.2019.01259</a>
    Open DOISearch in Google ScholarBack to article
  9. Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev. 2018; 17(10): 1002–1010. DOI: <a href="https://doi.org/10.1016/j.autrev.2018.04.008" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1016/j.autrev.2018.04.008</a>
    Open DOISearch in Google ScholarBack to article
  10. Nanda M, Nanda A, Al-Sabah H, Dvorak R, Alsaleh QA. Paraneoplastic pemphigus in association with B-cell lymphocytic leukemia and hepatitis C: favorable response to intravenous immunoglobulins and prednisolone. Int J Dermatol. 2007; 46(7): 767–9. DOI: <a href="https://doi.org/10.1111/j.1365-4632.2007.03225.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/j.1365-4632.2007.03225.x</a>
    Open DOISearch in Google ScholarBack to article
  11. Izaki S, Yoshizawa Y, Kitamura K, Kato H, Hashimoto H, Korman NJ, et al. Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis. Br J Dermatol. 1996; 134(5): 987–9. DOI: <a href="https://doi.org/10.1111/j.1365-2133.1996.tb06349.x" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/j.1365-2133.1996.tb06349.x</a>
    Open DOISearch in Google ScholarBack to article
  12. Lee A, Sandhu S, Imlay-Gillespie L, Mulligan S, Shumack S. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia. Australas J Dermatol. 2017; 58(4): e240–e242. DOI: <a href="https://doi.org/10.1111/ajd.12615" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/ajd.12615</a>
    Open DOISearch in Google ScholarBack to article
  13. Ito Y, Makita S, Maeshima AM, Hatta S, Suzuki T, Yuda S, et al. Paraneoplastic pemphigus associated with b-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab. Intern Med. 2018; 57(16): 2395–2398. DOI: <a href="https://doi.org/10.2169/internalmedicine.0578-17" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.2169/internalmedicine.0578-17</a>
    Open DOISearch in Google ScholarBack to article
  14. Vezzoli P, Berti E, Marzano AV. Rationale and efficacy for the use of rituximab in paraneoplastic pemphigus. Expert Rev Clin Immunol. 2008; 4(3): 351–63. DOI: <a href="https://doi.org/10.1586/1744666X.4.3.351" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1586/1744666X.4.3.351</a>
    Open DOISearch in Google ScholarBack to article
  15. Bech R, Baumgartner-Nielsen J, Peterslund NA, Steiniche T, Deleuran M, d’Amore F. Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus. Br J Dermatol. 2013; 169(2): 469–72. DOI: <a href="https://doi.org/10.1111/bjd.12324" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1111/bjd.12324</a>
    Open DOISearch in Google ScholarBack to article
  16. Gu L, Ye S. Tocilizumab cannot prevent the development of bronchiolitis obliterans in patients with castleman disease-associated paraneoplastic pemphigus. J Clin Rheumatol. 2019; 25(5): e77–e78. DOI: <a href="https://doi.org/10.1097/RHU.0000000000000675" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1097/RHU.0000000000000675</a>
    Open DOISearch in Google ScholarBack to article
  17. Lee J, Bloom R, Amber KT. A systematic review of patients with mucocutaneous and respiratory complications in paraneoplastic autoimmune multiorgan syndrome: Castleman's disease is the predominant malignancy. Lung. 2015; 193(4): 593–6. DOI: <a href="https://doi.org/10.1007/s00408-015-9732-8" target="_blank" rel="noopener noreferrer" class="text-signal-blue hover:underline">10.1007/s00408-015-9732-8</a>
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/fco-2022-0002 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 26 - 29
Submitted on: Apr 1, 2022
Accepted on: May 18, 2022
Published on: Sep 8, 2022
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
paraneoplastic pemphigus,
paraneoplastic syndromes,
cervical cancer,
gynaecological cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2022 O. Fiste, M. Liontos, A. Svarna, E. Gagari, F. Zagouri, M.A. Dimopoulos, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 13 (2022): Issue 1 (December 2022)Next article